Paper Details

  1. Home
  2. Paper Details

Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).

Author: , ClotetBonaventura, CrucetaAnna, CurranAdrian, DomingoPere, FerrerElena, GatellJose M, GuardoAlberto C, LoncàMontserrat, LozanoFrancisco, ManzardoChristian, MiroJose M, PlanaMontserrat, PodzamczerDaniel, PérezIñaki

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared an efavirenz-based regimen with 2 ritonavir-boosted protease inhibitor regimens in very immunosuppressed antiretroviral-naive, HIV-1-infected individuals.
Paper Details　
Original Abstract of the Article :
Few randomized clinical trials have investigated antiretroviral regimens in very advanced HIV-1-infected patients. The objective was to study the immune reconstitution in very immunosuppressed antiretroviral-naive, HIV-1-infected individuals by comparing an efavirenz-based regimen with 2 ritonavir-b...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/QAI.0000000000000567

データ提供：米国国立医学図書館（NLM）

Immune Reconstitution in Advanced HIV-1 Infection: A Journey Through the Desert of Treatment

HIV-1 infection is a complex and challenging condition, particularly for individuals with advanced immunosuppression. This study, the Advanz-3 trial, investigated the immune reconstitution in severely immunosuppressed, antiretroviral-naive individuals infected with HIV-1. The study compared the effects of an efavirenz-based regimen to two ritonavir-boosted protease inhibitor regimens (lopinavir-ritonavir or atazanavir-ritonavir) plus tenofovir/emtricitabine. The study's findings highlight the effectiveness of these antiretroviral regimens in promoting immune reconstitution in severely immunosuppressed individuals with HIV-1. The results demonstrate the importance of initiating antiretroviral therapy early in the course of HIV-1 infection to improve immune function and reduce the risk of disease progression.

A New Oasis: Restoring Immunity in Advanced HIV-1 Infection

This study offers hope for individuals with advanced HIV-1 infection, demonstrating that antiretroviral therapy can effectively promote immune reconstitution even in severely immunosuppressed individuals. The study's findings highlight the importance of early intervention in HIV-1 infection, emphasizing the need for timely diagnosis and treatment initiation to optimize immune recovery and improve long-term health outcomes.

A Pathway to Recovery: Managing HIV-1 Infection

This research underscores the crucial role of antiretroviral therapy in managing HIV-1 infection and preventing disease progression. The study's findings emphasize the importance of early diagnosis, prompt treatment initiation, and ongoing monitoring to optimize immune recovery and improve the quality of life for individuals living with HIV-1.

Dr.Camel's Conclusion

This study demonstrates the efficacy of antiretroviral therapy in promoting immune reconstitution in individuals with advanced HIV-1 infection. The findings highlight the importance of early intervention and underscore the need for ongoing research to develop even more effective treatment strategies for this challenging condition.

Date :
  1. Date Completed 2015-08-10
  2. Date Revised 2020-12-09
Further Info :

Pubmed ID

25831464

DOI: Digital Object Identifier

10.1097/QAI.0000000000000567

Related Literature

Article Analysis
・Side Effects of atazanavir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.